Page 47 - ITPS-8-2
P. 47
INNOSC Theranostics and
Pharmacological Sciences MDD biomarkers: Clinical implications
and Li et al. have recently conducted case–control studies www.webmd.com/depression/major-depression#1 [Last
in a Chinese cohort and established that the rs155979 accessed on 2024 Apr 20].
polymorphism in the lncRNA NONHSAT102891 was 2. Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-
significantly associated with depression susceptibility and resistant depression. Depress Anxiety. 2020;37(2):134-145.
risk of suicide. 87,88 doi: 10.1002/da.22968
5. Conclusion 3. Saloni Dattani LRG. Hannah Ritchie and Max Roser. Mental
Health Our World in Data-Online. Available from: https://
This review highlights the progress made in identifying ourworldindata.org/mental-health [Last accessed on
cellular and nuclear biomarkers for MDD. These biomarkers 2024 Mar 20].
hold promise for enhancing diagnostic accuracy, predicting 4. Ogbo FA, Mathsyaraja S, Koti RK, Perz J, Page A. The burden
treatment response, and personalizing therapeutic of depressive disorders in South Asia, 1990-2016: Findings
approaches. However, further research is required to from the global burden of disease study. BMC Psychiatry.
validate these biomarkers in clinical settings and to explore 2018;18(1):333.
their application in routine clinical practice. Despite doi: 10.1186/s12888-018-1918-1
extensive and advanced research, the cure for MDD is partial
and inadequate. Major challenges persist in screening, 5. GBD 2017 Disease and Injury Incidence and Prevalence
diagnosis, effective treatment, and prognosis. Identifying Collaborators. Global, regional, and national incidence,
specific genetic factors could enable personalized treatment prevalence, and years lived with disability for 354 diseases
and injuries for 195 countries and territories, 1990-2017:
strategies, potentially improving outcomes. A systematic analysis for the Global Burden of Disease Study
Acknowledgments 2017. Lancet. 2018;392(10159):1789-1858.
doi: 10.1016/S0140-6736(18)32279-7
None.
6. Redei EE, Mehta NS. Blood transcriptomic markers for
Funding major depression: From animal models to clinical settings.
Ann N Y Acad Sci. 2015;1344:37-49.
None.
doi: 10.1111/nyas.12748
Conflict of interest 7. Macaluso M, Preskorn SH. How biomarkers will change
The authors declare they have no competing interests. psychiatry: From clinical trials to practice. Part I:
Introduction. J Psychiatr Pract. 2012;18(2):118-121.
Author contributions doi: 10.1097/01.pra.0000413277.11091.25
Conceptualization: Najeeb Ullah 8. Kendler KS, Gardner CO, Prescott CA. Toward a
Formal analysis: Muhammad Ikram, Muhammad Imran comprehensive developmental model for major depression
Khan in women. Am J Psychiatry. 2002;159(7):1133-1145.
Supervision: Muhammad Ikram, Muhammad Imran Khan doi: 10.1176/appi.ajp.159.7.1133
Writing – original draft: Muhammad Kamran Ameer 9. Lohoff FW. Overview of the genetics of major depressive
Writing – review and editing: Fazal Wahab, Muhammad disorder. Curr Psychiatry Rep. 2010;12:539-546.
Imran Naseer
10. Keller MC, Fredrickson BL, Ybarra O, et al. A warm heart
Ethics approval and consent to participate and a clear head the contingent effects of weather on mood
and cognition. Psychol Sci. 2005;16(9):724-731.
Not applicable.
doi: 10.1111/j.1467-9280.2005.01602.x
Consent for publication 11. Nestler EJ, Peña CJ, Kundakovic M, Mitchell A, Akbarian S.
Epigenetic basis of mental illness. Neuroscientist.
Not applicable. 2016;22(5):447-463.
Availability of data doi: 10.1177/1073858415608147
Not applicable. 12. Krishnan V, Nestler EJ. The molecular neurobiology of
depression. Nature. 2008;455(7215):894-902.
References doi: 10.1038/nature07455
1. Bruce DF. Major Depression (Clinical Depression) Symptoms, 13. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized
Treatments, and More 2022; 2024. Available from: https:// controlled trial of the tumor necrosis factor antagonist
Volume 8 Issue 2 (2025) 41 doi: 10.36922/itps.4404

